Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML

Yun Wang, Shuzhao Chen, Shutong Liu, Zhijian Liang, Chunhua Li, Yang Liang

Blood (2025) 146 (Supplement 1): 771.

https://doi.org/10.1182/blood-2025-771

Published: 2025

Journal Articles

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef

Blood (2025) 146 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2025-2391

Published: 2025

Journal Articles

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

Jin Zhou, Qian Wang, Tao You, Yun Wang, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 7267.

https://doi.org/10.1182/blood-2025-7267

Published: 2025

Journal Articles

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

Qian Wang, Jin Zhou, Yun Wang, Tao You, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2025-3742

Published: 2025

Journal Articles

Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study

Longfei He, Haiwen Huang, Depei Wu, Tao You, Jin Zhou, Yun Wang, Wanying Chen, Chenwen Wang, Qian Cheng, Kaiyu Sheng

Blood (2025) 146 (Supplement 1): 7100.

https://doi.org/10.1182/blood-2025-7100

Published: 2025

Journal Articles

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

Xiaoqin Chen, Yun Wang, Zhijian Liang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2025) 146 (Supplement 1): 5829.

https://doi.org/10.1182/blood-2025-5829

Published: 2025

Journal Articles

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

Chenwen Wang, Jin Zhou, Tao You, Yun Wang, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 7256.

https://doi.org/10.1182/blood-2025-7256

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison

Tao You, Jin Zhou, Yun Wang, Chenwen Wang, Qian Wang, Xiao Ma, Peng Xu, Yuhu Feng, Jun Fang, Miao Zheng, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2025-1924

Published: 2025

Journal Articles

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Yun Wang, Chunhua Li, Robert Gale, Qi Liang, Neil Kay, Victoria Wang, Qianqian Huang, Yiling Song, Weida Wang, Yang Liang

Blood (2025) 146 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2025-2132

Published: 2025

Journal Articles

Mendelian randomization reveals the causative role of genetically predicted viral infection in pan-lymphoma risk

Wanying Chen, Jin Zhou, Qian Wang, Yun Wang, Depei Wu, Tao You, Haiwen Huang

Blood (2025) 146 (Supplement 1): 5449.

https://doi.org/10.1182/blood-2025-5449

Published: 2025

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Xiaoqin Chen, Yun Wang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2024) 144 (Supplement 1): 7025.

https://doi.org/10.1182/blood-2024-204564

Published: 2024

Journal Articles

Busulfan-Based Intensified Myeloablative Conditioning Regimen Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia-Single Center Study

Yun Wang, Ruijuan Sun, Yanli Zhao, Zhijie Wei, Min Xiong, Deyan Liu, Peihua Lu, Yue Lu

Blood (2024) 144 (Supplement 1): 7328.

https://doi.org/10.1182/blood-2024-202905

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Blood (2024) 144 (Supplement 1): 971.

https://doi.org/10.1182/blood-2024-202801

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

Yun Wang, Weida Wang, Jingbo Xu, Ji Ma, Hua Wang, Bingyi Wu, Yuanbin Song, Weiran Lv, Lezong Chen, Jun Ma, Tiejun Gong, Yang Liang

Blood (2024) 144 (Supplement 1): 6074.

https://doi.org/10.1182/blood-2024-209055

Published: 2024

Journal Articles

FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages

Yun Wang, Shuzhao Chen, Limei Zhang, Jiangtao Song, Huaze Liao, Mayan Huang, Kunying Xie, Robert Peter Gale, Yang Liang

Blood (2023) 142 (Supplement 1): 2962.

https://doi.org/10.1182/blood-2023-190969

Published: 2023

Journal Articles

The Role of Gpibα in Control of Megakaryocyte Reactivity to Thrombopoietin

Fengjiao Han, Qiuyu Guo, Yun Wang, Zihan Zhang, Qi Feng, Jun Peng, Ming Hou, Heyu Ni, Miao Xu

Blood (2023) 142 (Supplement 1): 1219.

https://doi.org/10.1182/blood-2023-179047

Published: 2023

Journal Articles

Efficacy and Safety of Avatrombopag on Thrombocytopenia after Chemotherapy in Acute Leukaemia

Xiaoli Chen, Mengxing Xue, Qian Wu, Yun Wang, Ailing Deng, Xueqing Dou, Yuhua Ru, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2023-188839

Published: 2023

Journal Articles

Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Monzr M. Al Malki, Alla Keyzner, Hyung Chan Suh, Aasiya Matin, Erica Buonomo, Yun Wang, Nina Abelowitz, Jim Murray, Gavin Macbeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef

Blood (2023) 142 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2023-187355

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Mendelian randomization reveals the causative role of genetically predicted viral infection in pan-lymphoma risk

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Busulfan-Based Intensified Myeloablative Conditioning Regimen Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia-Single Center Study

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages

The Role of Gpibα in Control of Megakaryocyte Reactivity to Thrombopoietin

Efficacy and Safety of Avatrombopag on Thrombocytopenia after Chemotherapy in Acute Leukaemia

Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only